ExampleResearch writingMedicine & healthcare

Example literature review: IL-15, intraepithelial lymphocytes, regulatory T cells and anti-endomysial antibody in coeliac disease (annotated)

An annotated literature review on the immune mechanisms of coeliac disease, from IL-15 and intraepithelial lymphocytes to regulatory cells and the anti-endomysial antibody. It helps PhD scholars in immunology and biomedical science structure a mechanistic review and use every source accurately.

What you will learn

  • Frame a mechanistic review with a precise definition and scope
  • Synthesise evidence on IL-15 and intraepithelial lymphocytes across human and animal studies
  • Explain how IL-15 can undermine regulation without damaging regulatory cells
  • Distinguish a diagnostic marker such as EmA from a disease mechanism
  • Check that the title, the sources and the claims match

What you will unlearn

  • Coeliac disease is an infection.It is an immune-mediated enteropathy triggered by gluten in genetically susceptible people.
  • IL-15 in coeliac disease comes from CD4+ T cells.It comes mainly from epithelial and dendritic cells; CD4+ T cells contribute IL-21 and IFN-γ.
  • More regulatory T cells in the gut means better control of inflammation.IL-15 can make effector cells resistant to regulation, so regulatory cells may increase yet fail.
  • Any paper that mentions the disease can support a mechanism.Cite each source only for what it actually studied.

Skills you will practise

  • Biomedical literature review
  • Immunology
  • Source verification
  • Thematic synthesis
  • Evidence grading

About this example

This page is the literature review chapter of an example doctoral thesis in immunology. The planned laboratory study asks how interleukin-15 (IL-15) and the coeliac autoantibody response relate to the behaviour of intestinal regulatory T cells in coeliac (celiac) disease. The review therefore covers the immune basis of the disease, the role of IL-15 in activating intraepithelial lymphocytes (IELs), how IL-15 affects regulatory cells, what the anti-endomysial antibody (EmA) tells us, and the gaps the study will address.

It is an illustrative teaching example, not a real student's work. Do not submit any part of it as your own work; your university's academic integrity rules apply.

The example: scope and immune basis of the disease

2.1 Scope

This chapter reviews research on the innate and adaptive immune mechanisms of coeliac disease, with a focus on IL-15, IELs, regulatory T cells and EmA. Sources are reviews, laboratory studies in human tissue and animal models, and a systematic review of prevalence. Clinical management is discussed only where it bears on these mechanisms.

2.2 An immune-mediated disease with adaptive and innate arms

Coeliac disease is a chronic immune-mediated enteropathy triggered by dietary gluten in genetically susceptible people who carry HLA-DQ2 or HLA-DQ8 (Green et al., 2015). It is not an infection. A systematic review estimated a pooled global prevalence of 1.4% based on serology and 0.7% based on biopsy (Singh et al., 2018). In the adaptive arm, gluten peptides cross the epithelium, are modified by tissue transglutaminase (TG2) and presented by HLA-DQ2 or DQ8 to CD4+ T cells in the lamina propria, which release cytokines such as interferon-gamma (IFN-γ) and IL-21 and help B cells produce antibodies to gliadin and TG2 (Parzanese et al., 2017; Kaur et al., 2017). In the innate arm, stressed enterocytes express non-classical MHC class I molecules such as MICA and HLA-E, which are recognised by activating natural killer receptors on IELs (Setty et al., 2008; Malamut et al., 2019).

The example: IL-15 and intraepithelial lymphocytes

2.3 IL-15 as a driver of IEL activation

A defining feature of active coeliac disease is a rise in IELs, especially cytotoxic CD8+ cells (Parzanese et al., 2017). IL-15, produced mainly by intestinal epithelial cells and dendritic cells, promotes the growth and cytotoxic activity of these cells; in established disease, CD8+ IELs show increased granzyme B and express the activating receptors NKG2D and CD94-NKG2C, enabling them to kill epithelial cells that display MICA and HLA-E (Malamut et al., 2019). CD4+ T cells contribute indirectly, through IL-21 and IFN-γ, which amplify IEL activation (Kaur et al., 2017; Abadie & Jabri, 2014). Animal and human tissue studies add mechanistic detail: epithelial IL-15 regulates the movement of γδ IELs within the mucosa in mice (Hu et al., 2018), and IL-15 and NOTCH1 signals drive the development of a population of innate-like IELs that can transform into lymphomas in refractory coeliac disease (Ettersperger et al., 2016).

The example: IL-15 and regulatory cells

2.4 Why regulation fails in active disease

If regulatory T cells are present in the inflamed mucosa, why do they not control the immune response? Reviewing work from human tissue and mouse models, Abadie and Jabri (2014) conclude that IL-15 acts on the effector cells rather than damaging regulatory cells themselves. IL-15 impairs the response of effector T cells to transforming growth factor beta (TGF-β), a key mediator of regulation, by activating the JNK pathway and interfering with Smad3-dependent signalling, and it also activates the PI3K pathway, which makes CD8+ effector cells resistant to suppression. This would explain why regulatory cells can increase in number during active disease yet fail to restrain inflammation.

Regulation in the epithelium may also come from unexpected cells. In intestinal biopsies from 38 patients with coeliac disease and 10 controls, Bhagat et al. (2008) found that a subset of CD8+ IELs expressing the γδ T-cell receptor and the inhibitory receptor NKG2A behaved like regulatory cells: they produced TGF-β1 and reduced the cytotoxic programming of conventional CD8+ IELs stimulated with IL-15. These cells were more frequent in patients on a gluten-free diet than in those with active disease.

The example: anti-endomysial antibody and diagnosis

2.5 What EmA measures

EmA and antibodies to TG2 are markers of the autoimmune response in coeliac disease; TG2 is the main target antigen of this response, and IgA deposits against TG2 can be found in the intestine before overt disease develops (López Casado et al., 2018). In clinical practice, EmA is highly specific, and Caio et al. (2019) note that its diagnostic accuracy is highest when the test is read by experienced staff in specialist laboratories. The systematic review of prevalence counted people as seropositive if they had either anti-TG2 antibody or EmA (Singh et al., 2018). For the present study, EmA is therefore treated as a marker of the adaptive autoimmune response, not as a cause of regulatory T-cell changes; any link between the two is an open question.

2.6 IL-15 as a therapeutic target

The established treatment for coeliac disease remains a strict, lifelong gluten-free diet (Green et al., 2015). A small group of patients have refractory disease, in which symptoms and intestinal damage persist despite the diet; in its more severe form, abnormal IELs expand and can progress to lymphoma (Malamut et al., 2019; Ettersperger et al., 2016). These patients are the main reason for interest in therapies that act on the immune mechanisms reviewed above.

Because IL-15 sits at the centre of IEL activation and resistance to regulation, blocking it has been explored as a treatment, particularly for refractory coeliac disease. Vicari et al. (2017) described a humanised anti-IL-15 antibody and its potential relevance for refractory coeliac disease and eosinophilic oesophagitis. Its clinical value depends on trials published after the sources reviewed here.

The example: evidence summary and gaps

2.7 Summary of the evidence by type of study

Table 2.1. Evidence reviewed, grouped by type of study.
Type of evidenceSourcesMain contribution
Narrative reviews(Green et al., 2015; Kaur et al., 2017; Parzanese et al., 2017; López Casado et al., 2018; Malamut et al., 2019; Caio et al., 2019; Abadie & Jabri, 2014)Mechanisms of adaptive and innate immunity; IL-15 and regulation; diagnostic role of EmA
Human tissue studies(Bhagat et al., 2008; Ettersperger et al., 2016)Regulatory-like IELs; IL-15-dependent innate IELs and lymphoma
Animal and laboratory studies(Hu et al., 2018; Vicari et al., 2017)IL-15 and IEL motility; anti-IL-15 antibody
Systematic review(Singh et al., 2018)Global prevalence by serology and biopsy

Three gaps follow. First, most evidence on IL-15 and regulation comes from reviews and a small number of tissue studies, and direct measurements of regulatory T-cell function in human coeliac mucosa remain few. Second, no source reviewed here links EmA levels to regulatory T-cell behaviour. Third, the newest sources date from 2019, so recent work on diagnostic guidelines and IL-15 blockade must be added before the thesis is submitted.

How to adapt this to your own study

  1. Check that every topic named in your title has its own section, backed by sources.
  2. Open with a short framing section and a precise definition of the condition or phenomenon.
  3. Organise the argument by theme or mechanism, and use a table to show the types of evidence.
  4. State whether each finding comes from human tissue, animals or cell culture.
  5. Check that each source actually supports the claim you cite it for.
  6. Name the cell or molecule responsible for each effect once, consistently.
  7. Search again for recent work before submission and say how current your review is.

Common mistakes in a biomedical literature review

  • A title that promises topics the review does not cover.
  • Citing a source for a mechanism it does not study (here, a single case report of wheat allergy).
  • Contradicting yourself about which cells produce a cytokine.
  • Typographical errors in key terms (IFN-c for IFN-γ) and truncated sentences.
  • Vague superlatives ("one of the most prevalent") instead of cited estimates.
  • Treating a diagnostic marker as a cause.
  • Relying on sources several years old in a fast-moving field without saying so.
How this literature review meets common examiner expectations.
What examiners look forWhere this example does itCheck in your own draft
Coverage that matches the title2.4 and 2.5 added for regulatory cells and EmAIs every title term covered?
Accurate use of sourcesMisattributed case report removedDoes each source say what you cite it for?
Correct scienceCytokine sources and terminology correctedHave you checked every mechanism?
Synthesis by theme2.3 to 2.6, with Table 2.1 by study typeAre you arguing, not listing?
Evidence strength shownHuman, animal and review evidence distinguishedIs the type of evidence clear?
Specific gaps2.7Do your gaps lead to your research questions?

Key takeaways

  • Coeliac disease combines a gluten-specific adaptive response with innate activation of IELs (Parzanese et al., 2017; Malamut et al., 2019).
  • IL-15 from epithelial and dendritic cells drives IEL cytotoxicity (Malamut et al., 2019).
  • IL-15 can make effector cells resistant to regulation through effects on TGF-β signalling (Abadie & Jabri, 2014).
  • EmA is a highly specific diagnostic marker, not evidence of a mechanism (Caio et al., 2019).
  • Make sure every term in your title is covered and every source supports its claim.
Your next step

Want to apply this to your own study?

  1. 1Tell us your topic, data and deadline
  2. 2A subject mentor reviews your work with you
  3. 3You get a plan and a quote
Literature review

References

  1. Abadie, V., & Jabri, B. (2014). IL-15: A central regulator of celiac disease immunopathology. Immunological Reviews, 260(1), 221–234. https://doi.org/10.1111/imr.12191
  2. Bhagat, G., Naiyer, A. J., Shah, J. G., Harper, J., Jabri, B., Wang, T. C., Green, P. H. R., & Manavalan, J. S. (2008). Small intestinal CD8+TCRγδ+NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. Journal of Clinical Investigation, 118(1), 281–293. https://doi.org/10.1172/JCI30989
  3. Caio, G., Volta, U., Sapone, A., Leffler, D. A., De Giorgio, R., Catassi, C., & Fasano, A. (2019). Celiac disease: A comprehensive current review. BMC Medicine, 17(1), 142. https://doi.org/10.1186/s12916-019-1380-z
  4. Ettersperger, J., Montcuquet, N., Malamut, G., Guegan, N., Lopez-Lastra, S., Gayraud, S., Reimann, C., Vidal, E., Cagnard, N., Villarese, P., Andre-Schmutz, I., Gomes Domingues, R., Godinho-Silva, C., Veiga-Fernandes, H., Lhermitte, L., Asnafi, V., Macintyre, E., Cellier, C., Beldjord, K., . . . Meresse, B. (2016). Interleukin-15-dependent T-cell-like innate intraepithelial lymphocytes develop in the intestine and transform into lymphomas in celiac disease. Immunity, 45(3), 610–625. https://doi.org/10.1016/j.immuni.2016.07.018
  5. Green, P. H. R., Lebwohl, B., & Greywoode, R. (2015). Celiac disease. Journal of Allergy and Clinical Immunology, 135(5), 1099–1106. https://doi.org/10.1016/j.jaci.2015.01.044
  6. Hu, M. D., Ethridge, A. D., Lipstein, R., Kumar, S., Wang, Y., Jabri, B., Turner, J. R., & Edelblum, K. L. (2018). Epithelial IL-15 is a critical regulator of γδ intraepithelial lymphocyte motility within the intestinal mucosa. Journal of Immunology, 201(2), 747–756. https://doi.org/10.4049/jimmunol.1701603
  7. Kaur, A., Shimoni, O., & Wallach, M. (2017). Celiac disease: From etiological factors to evolving diagnostic approaches. Journal of Gastroenterology, 52(9), 1001–1012. https://doi.org/10.1007/s00535-017-1357-7
  8. López Casado, M. Á., Lorite, P., Ponce de León, C., Palomeque, T., & Torres, M. I. (2018). Celiac disease autoimmunity. Archivum Immunologiae et Therapiae Experimentalis, 66(6), 423–430. https://doi.org/10.1007/s00005-018-0520-z
  9. Malamut, G., Cording, S., & Cerf-Bensussan, N. (2019). Recent advances in celiac disease and refractory celiac disease. F1000Research, 8. https://doi.org/10.12688/f1000research.18701.1
  10. Parzanese, I., Qehajaj, D., Patrinicola, F., Aralica, M., Chiriva-Internati, M., Stifter, S., Elli, L., & Grizzi, F. (2017). Celiac disease: From pathophysiology to treatment. World Journal of Gastrointestinal Pathophysiology, 8(2), 27–38. https://doi.org/10.4291/wjgp.v8.i2.27
  11. Setty, M., Hormaza, L., & Guandalini, S. (2008). Celiac disease: Risk assessment, diagnosis, and monitoring. Molecular Diagnosis & Therapy, 12, 289–298. https://link.springer.com/article/10.1007/BF03256294
  12. Singh, P., Arora, A., Strand, T. A., Leffler, D. A., Catassi, C., Green, P. H., Kelly, C. P., Ahuja, V., & Makharia, G. K. (2018). Global prevalence of celiac disease: Systematic review and meta-analysis. Clinical Gastroenterology and Hepatology, 16(6), 823–836.e2. https://doi.org/10.1016/j.cgh.2017.06.037
  13. Vicari, A. P., Schoepfer, A. M., Meresse, B., Goffin, L., Léger, O., Josserand, S., Guégan, N., Yousefi, S., Straumann, A., Cerf-Bensussan, N., Simon, H.-U., & Chvatchko, Y. (2017). Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis. MAbs, 9(6), 927–944. https://doi.org/10.1080/19420862.2017.1332553

How to cite this article

Choose your referencing style, then copy. Check your university's or journal's guide for local variations.

PhD Research Lab Academy. (2023, February 18). Example literature review: IL-15, intraepithelial lymphocytes, regulatory T cells and anti-endomysial antibody in coeliac disease (annotated). PhD Research Lab. https://www.phdassistance.com/sample-work/involvement-of-anti-endomysial-antibody/

PhD Research Lab Academy. “Example Literature Review: IL-15, Intraepithelial Lymphocytes, Regulatory T Cells and Anti-endomysial Antibody in Coeliac Disease (annotated).” PhD Research Lab, 18 Feb. 2023, www.phdassistance.com/sample-work/involvement-of-anti-endomysial-antibody. Accessed [access date].

PhD Research Lab Academy (2023) Example literature review: IL-15, intraepithelial lymphocytes, regulatory T cells and anti-endomysial antibody in coeliac disease (annotated). PhD Research Lab. Available at: https://www.phdassistance.com/sample-work/involvement-of-anti-endomysial-antibody/ (Accessed: [access date]).

PhD Research Lab Academy. “Example Literature Review: IL-15, Intraepithelial Lymphocytes, Regulatory T Cells and Anti-endomysial Antibody in Coeliac Disease (annotated).” PhD Research Lab. February 18, 2023. https://www.phdassistance.com/sample-work/involvement-of-anti-endomysial-antibody.

PhD Research Lab Academy, ‘Example Literature Review: IL-15, Intraepithelial Lymphocytes, Regulatory T Cells and Anti-endomysial Antibody in Coeliac Disease (annotated)’ (PhD Research Lab, 18 February 2023) <https://www.phdassistance.com/sample-work/involvement-of-anti-endomysial-antibody> accessed [access date].

PhD Research Lab Academy. Example literature review: IL-15, intraepithelial lymphocytes, regulatory T cells and anti-endomysial antibody in coeliac disease (annotated) [Internet]. PhD Research Lab; 2023 Feb 18 [cited [access date]]. Available from: https://www.phdassistance.com/sample-work/involvement-of-anti-endomysial-antibody/

PhD Research Lab Academy, “Example literature review: IL-15, intraepithelial lymphocytes, regulatory T cells and anti-endomysial antibody in coeliac disease (annotated),” PhD Research Lab, Feb. 18, 2023. [Online]. Available: https://www.phdassistance.com/sample-work/involvement-of-anti-endomysial-antibody. [Accessed: [access date]].

@online{involvement_of_anti_endomysial_antibody_2023,
  author = {{PhD Research Lab Academy}},
  title = {{Example literature review: IL-15, intraepithelial lymphocytes, regulatory T cells and anti-endomysial antibody in coeliac disease (annotated)}},
  organization = {PhD Research Lab},
  date = {2023-02-18},
  url = {https://www.phdassistance.com/sample-work/involvement-of-anti-endomysial-antibody},
  urldate = {[access date]}
}

This article is for learning. Use it to understand the method and cite the original sources above in your own work; do not copy or submit it as your own.

Example literature reviewNeed help applying it to your study?
Literature review